Radiation and chemotherapy for patients with stage III non-small cell lung cancer

Mark R. Green, Caio M. Rocha Lima, Carol A. Sherman

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Nearly 50,000 people in the United States will be diagnosed with stage III non-small cell lung cancer during the year 2000. Over the past 10 years, combined modality therapy has become the standard of care for primary treatment of most of these patients. Numerous studies and meta-analyses document an improvement in survival for patients with stage III disease treated with sequential chemotherapy followed by chest radiation, compared with radiation alone. Some more recent studies have shown a further improvement in survival when the chemotherapy and full-dose radiation are given concurrently. Acute toxicity is increased compared with sequential chemotherapy followed by radiation, but late toxicities seem similar. A current question under study is whether the use of initial chemotherapy followed by concurrent chemoradiotherapy will further improve median and overall survival compared with immediate concurrent therapy alone. Copyright (C) 2000 by W.B. Saunders Company.

Original languageEnglish
Pages (from-to)289-295
Number of pages7
JournalSeminars in Radiation Oncology
Volume10
Issue number4
StatePublished - Oct 30 2000

Fingerprint

chemotherapy
Non-Small Cell Lung Carcinoma
lungs
cancer
Radiation
Drug Therapy
radiation
toxicity
Survival
therapy
Combined Modality Therapy
chest
Chemoradiotherapy
Standard of Care
Meta-Analysis
Thorax
dosage
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Radiation

Cite this

Green, M. R., Rocha Lima, C. M., & Sherman, C. A. (2000). Radiation and chemotherapy for patients with stage III non-small cell lung cancer. Seminars in Radiation Oncology, 10(4), 289-295.

Radiation and chemotherapy for patients with stage III non-small cell lung cancer. / Green, Mark R.; Rocha Lima, Caio M.; Sherman, Carol A.

In: Seminars in Radiation Oncology, Vol. 10, No. 4, 30.10.2000, p. 289-295.

Research output: Contribution to journalArticle

Green, MR, Rocha Lima, CM & Sherman, CA 2000, 'Radiation and chemotherapy for patients with stage III non-small cell lung cancer', Seminars in Radiation Oncology, vol. 10, no. 4, pp. 289-295.
Green, Mark R. ; Rocha Lima, Caio M. ; Sherman, Carol A. / Radiation and chemotherapy for patients with stage III non-small cell lung cancer. In: Seminars in Radiation Oncology. 2000 ; Vol. 10, No. 4. pp. 289-295.
@article{17c9ff9e375a487388ffdfa53bbc07f2,
title = "Radiation and chemotherapy for patients with stage III non-small cell lung cancer",
abstract = "Nearly 50,000 people in the United States will be diagnosed with stage III non-small cell lung cancer during the year 2000. Over the past 10 years, combined modality therapy has become the standard of care for primary treatment of most of these patients. Numerous studies and meta-analyses document an improvement in survival for patients with stage III disease treated with sequential chemotherapy followed by chest radiation, compared with radiation alone. Some more recent studies have shown a further improvement in survival when the chemotherapy and full-dose radiation are given concurrently. Acute toxicity is increased compared with sequential chemotherapy followed by radiation, but late toxicities seem similar. A current question under study is whether the use of initial chemotherapy followed by concurrent chemoradiotherapy will further improve median and overall survival compared with immediate concurrent therapy alone. Copyright (C) 2000 by W.B. Saunders Company.",
author = "Green, {Mark R.} and {Rocha Lima}, {Caio M.} and Sherman, {Carol A.}",
year = "2000",
month = "10",
day = "30",
language = "English",
volume = "10",
pages = "289--295",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Radiation and chemotherapy for patients with stage III non-small cell lung cancer

AU - Green, Mark R.

AU - Rocha Lima, Caio M.

AU - Sherman, Carol A.

PY - 2000/10/30

Y1 - 2000/10/30

N2 - Nearly 50,000 people in the United States will be diagnosed with stage III non-small cell lung cancer during the year 2000. Over the past 10 years, combined modality therapy has become the standard of care for primary treatment of most of these patients. Numerous studies and meta-analyses document an improvement in survival for patients with stage III disease treated with sequential chemotherapy followed by chest radiation, compared with radiation alone. Some more recent studies have shown a further improvement in survival when the chemotherapy and full-dose radiation are given concurrently. Acute toxicity is increased compared with sequential chemotherapy followed by radiation, but late toxicities seem similar. A current question under study is whether the use of initial chemotherapy followed by concurrent chemoradiotherapy will further improve median and overall survival compared with immediate concurrent therapy alone. Copyright (C) 2000 by W.B. Saunders Company.

AB - Nearly 50,000 people in the United States will be diagnosed with stage III non-small cell lung cancer during the year 2000. Over the past 10 years, combined modality therapy has become the standard of care for primary treatment of most of these patients. Numerous studies and meta-analyses document an improvement in survival for patients with stage III disease treated with sequential chemotherapy followed by chest radiation, compared with radiation alone. Some more recent studies have shown a further improvement in survival when the chemotherapy and full-dose radiation are given concurrently. Acute toxicity is increased compared with sequential chemotherapy followed by radiation, but late toxicities seem similar. A current question under study is whether the use of initial chemotherapy followed by concurrent chemoradiotherapy will further improve median and overall survival compared with immediate concurrent therapy alone. Copyright (C) 2000 by W.B. Saunders Company.

UR - http://www.scopus.com/inward/record.url?scp=0033784916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033784916&partnerID=8YFLogxK

M3 - Article

C2 - 11040329

AN - SCOPUS:0033784916

VL - 10

SP - 289

EP - 295

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 4

ER -